India · Delayed Price · Currency is INR Concord Biotech Statistics
Total Valuation
Concord Biotech has a market cap or net worth of INR 125.70 billion. The enterprise value is 121.54 billion.
| Market Cap | 125.70B |
| Enterprise Value | 121.54B |
Important Dates
The last earnings date was Friday, May 29, 2026.
| Earnings Date | May 29, 2026 |
| Ex-Dividend Date | Jul 24, 2026 |
Share Statistics
| Current Share Class | 104.62M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.64% |
| Shares Change (QoQ) | -1.21% |
| Owned by Insiders (%) | 60.90% |
| Owned by Institutions (%) | 15.41% |
| Float | 26.60M |
Valuation Ratios
The trailing PE ratio is 48.18 and the forward PE ratio is 38.07.
| PE Ratio | 48.18 |
| Forward PE | 38.07 |
| PS Ratio | 11.92 |
| PB Ratio | 6.24 |
| P/TBV Ratio | 6.24 |
| P/FCF Ratio | 73.19 |
| P/OCF Ratio | 47.10 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 32.82, with an EV/FCF ratio of 70.78.
| EV / Earnings | 46.59 |
| EV / Sales | 11.52 |
| EV / EBITDA | 32.82 |
| EV / EBIT | 41.08 |
| EV / FCF | 70.78 |
Financial Position
The company has a current ratio of 7.39, with a Debt / Equity ratio of 0.00.
| Current Ratio | 7.39 |
| Quick Ratio | 5.18 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | 0.01 |
| Interest Coverage | 1,034.40 |
Financial Efficiency
Return on equity (ROE) is 13.54% and return on invested capital (ROIC) is 14.22%.
| Return on Equity (ROE) | 13.54% |
| Return on Assets (ROA) | 8.58% |
| Return on Invested Capital (ROIC) | 14.22% |
| Return on Capital Employed (ROCE) | 14.18% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 6.71M |
| Profits Per Employee | 1.66M |
| Employee Count | 1,571 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 1.28 |
Taxes
In the past 12 months, Concord Biotech has paid 854.18 million in taxes.
| Income Tax | 854.18M |
| Effective Tax Rate | 24.78% |
Stock Price Statistics
The stock price has decreased by -35.98% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -35.98% |
| 50-Day Moving Average | 1,096.16 |
| 200-Day Moving Average | 1,338.62 |
| Relative Strength Index (RSI) | 59.86 |
| Average Volume (20 Days) | 30,960 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Concord Biotech had revenue of INR 10.55 billion and earned 2.61 billion in profits. Earnings per share was 24.78.
| Revenue | 10.55B |
| Gross Profit | 6.93B |
| Operating Income | 2.93B |
| Pretax Income | 3.45B |
| Net Income | 2.61B |
| EBITDA | 3.67B |
| EBIT | 2.93B |
| Earnings Per Share (EPS) | 24.78 |
Balance Sheet
The company has 4.16 billion in cash and 23.16 million in debt, with a net cash position of 4.13 billion.
| Cash & Cash Equivalents | 4.16B |
| Total Debt | 23.16M |
| Net Cash | 4.13B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 20.15B |
| Book Value Per Share | 192.53 |
| Working Capital | 10.81B |
Cash Flow
In the last 12 months, operating cash flow was 2.67 billion and capital expenditures -951.51 million, giving a free cash flow of 1.72 billion.
| Operating Cash Flow | 2.67B |
| Capital Expenditures | -951.51M |
| Depreciation & Amortization | 744.59M |
| Net Borrowing | -6.54M |
| Free Cash Flow | 1.72B |
| FCF Per Share | n/a |
Margins
Gross margin is 65.70%, with operating and profit margins of 27.77% and 24.73%.
| Gross Margin | 65.70% |
| Operating Margin | 27.77% |
| Pretax Margin | 32.67% |
| Profit Margin | 24.73% |
| EBITDA Margin | 34.83% |
| EBIT Margin | 27.77% |
| FCF Margin | 16.28% |
Dividends & Yields
This stock pays an annual dividend of 18.25, which amounts to a dividend yield of 1.52%.
| Dividend Per Share | 18.25 |
| Dividend Yield | 1.52% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | 73.65% |
| Buyback Yield | -0.64% |
| Shareholder Yield | 1.10% |
| Earnings Yield | 2.08% |
| FCF Yield | 1.37% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Concord Biotech is 1,196.00, which is -0.35% lower than the current price. The consensus rating is "Buy".
| Price Target | 1,196.00 |
| Price Target Difference | -0.35% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 16.61% |
| EPS Growth Forecast (3Y) | 27.28% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |